Study wrapper · #697
Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.
Editor's note
A foundational entry in the group's series: RNA-seq in a rat stroke model identified 394 genes differentially expressed with Semax versus saline 24 hours after occlusion, with the peptide suppressing inflammation-related genes and activating neurotransmission-related genes, mirror-imaging the pattern ischemia produced. This established the compensation-of-disrupted-expression framework the later papers build on. As mechanistic preclinical work it is coherent and internally consistent, but remains gene-expression-level, single-model and single-lab, without behavioral or clinical endpoints. Useful as the mechanistic backbone of the Semax stroke story. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
This rat study is a cornerstone of the research showing how Semax might protect the brain after a stroke. One day after a temporary stroke, the researchers compared gene activity in rats given Semax versus those given salt water. They found 394 genes that behaved differently with Semax. The pattern was telling: Semax quieted genes driving inflammation and boosted genes involved in nerve-cell communication, essentially the opposite of what the stroke itself did. The authors describe Semax as helping restore the normal gene pattern that a stroke disrupts. This framework underlies much of the group's later work. It is detailed laboratory gene-analysis in rats meant to explain mechanism; it does not test Semax as a treatment in humans and includes no clinical outcomes.